Subscribe to newsletters
Wednesday, January 2, 2013
What is already known about this subject: Observation from clinical studies have demonstrated that: • CYP2C19 genotype does not have a clinically relevant effect on active metabolite concentrations or platelet inhibition in prasugrel-treated subjects • Variability of response to clopidogrel active metabolite and reduced platelet inhibition lead to increased adverse cardiovascular events in patients with acute coronary syndromes
details
Wednesday, January 2, 2013
What is already known about this subject: A number of pharmacokinetics studies have focused on S-warfarin. These have shown that demographic factors, such as bodyweight, genetic factors, such as CYP2C9 genotype, and interacting medicines, particularly amiodarone, contribute to the interindividual estimates of clearance. What this study adds: This study not only reinforces what has previously been learned about S-warfarin, but also provides an insight into the pharmacokinetics of R-warfarin.
details
Wednesday, December 19, 2012
January 2013 Newsletter is available to download. Special points of interest: 1. Awareness of lupus anticoagulants in drug therapy 2. New product, Entamoeba histolytica IgG 3. Research portfolio grows
details
Tuesday, December 18, 2012
Quadratech supplies high quality Epigenetic Peptides and Antibodies, Custom Peptides, Custom Antibodies, Antibodies to Selected Targets and Bioactive Peptides. These have been successfully used in many research laboratories.
details
Tuesday, December 18, 2012
Amyloid Precursor Protein (APP) is a transmembrane protein that is predominantly expressed in the brain. Mutations and subsequent cleavages of APP by β-secretase, ϒ-secretase and caspases generated amyloid beta peptides, which have been implicated in the pathogenesis of Alzheimer's disease. Proteolytic action of β-secretase and ϒ-secretase generates amyloid β peptides of 40 or 42 residues. These peptides are susceptible to aggregate and lead to formation of amyloid plaques that characterizes Alzheimer disease.
details
Friday, December 14, 2012
Bio-Synthesis Inc. Introduces "BNA-NC" - A Third Generation Multi Functional Bridged Nucleic Acid Bio-Synthesis is proud to announce that it has acquired a license from BNA Inc. of Osaka, Japan for the manufacturing and distribution of BNA-NC, a third generation of BNA oligonucleotides. This agreement is valid worldwide and is meant for research use only at this time (Patents JP: 4731324(2011.4.28), USP: 7427672(2008.9.23), EP: 1551905(2012.4.25)).
details
Friday, December 14, 2012
Biomedical Applications of Glycopeptides Diagnostics–Glycated peptides can serve as biomarkers to monitor the onset of diseases such as hyperglycemia, diabetes and its complications. Studies have shown that in diabetic patients,proteins including Hemoglobin A, Human Serum Albumin(HSA),Fibrinogen are extensively glycated. Diseases Therapy–age–related neurodegenerative diseases such as Alzheimer’s disease and amyotrophic lateral sclerosis have been associated with increased AGE’s formation.Glycopeptides can therefore serve as biological markers to evaluate the efficacy of disease therapy.
details
Friday, December 14, 2012
Bio-Synthesis is a leading global manufacturer of high quality custom peptides and oligonucleotides. Their expertise includes the ability to design and manufacture advanced peptide-bioplymer bioconjugation for biopharmaceutical, diagnostic, and research applications.
details
Friday, December 14, 2012
Back issues of Quadratech 2012 newsletters are available for viewing and downloading.
details
Friday, December 7, 2012
Direct Thrombin Inhibitors (DTIs) have increasing and promising curative, preventive or prophylactic applications in severe clinical situations. Laboratory methods are required for adjustment of drug efficacy and for avoiding overdosage. Specialized calibrated clotting and chromogenic assays for quantitating various DTIs have been developed and compared for their efficacy. Results show excellent performance with Hirudin and analogues, but were not found to be suitable for the Argatroban® usual therapeutic range.
details
Previous 1 2 3 4 Next
Powered by nopcommerce